{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:31:24Z","timestamp":1775626284915,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.lungcan.2020.05.023","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T11:41:59Z","timestamp":1590061319000},"page":"86-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells"],"prefix":"10.1016","volume":"146","author":[{"given":"Kenji","family":"Otsuka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Mitsuhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisatsugu","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Hanibuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohisa","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuro","family":"Saijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kozai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Tobiume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Kishuku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2020.05.023_bib0005","first-page":"1","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","author":"Carbone","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.lungcan.2020.05.023_bib0010","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jtho.2018.06.011","article-title":"Scientific advances and new frontiers in mesothelioma therapeutics","volume":"13","author":"Mutti","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2020.05.023_bib0015","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jtho.2018.02.021","article-title":"Progress in the management of malignant pleural mesothelioma in 2017","volume":"13","author":"McCambridge","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.05.023_bib0020","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol."},{"issue":"6382","key":"10.1016\/j.lungcan.2020.05.023_bib0025","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.lungcan.2020.05.023_bib0030","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/annonc\/mdx755","article-title":"Comprehensive analysis of the clinical immune-oncology landscape","volume":"29","author":"Tang","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.05.023_bib0035","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","author":"Okada","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.lungcan.2020.05.023_bib0040","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabr\u00f2","year":"2018","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2020.05.023_bib0045","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2020.05.023_bib0050","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"French Cooperative Thoracic Intergroup. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicenter, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2020.05.023_bib0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.lungcan.2020.05.023_bib0060","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10189","key":"10.1016\/j.lungcan.2020.05.023_bib0065","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicenter, open-label, phase 3, randomised control trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.lungcan.2020.05.023_bib0070","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutation burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.lungcan.2020.05.023_bib0075","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.lungcan.2020.05.023_bib0080","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2020.05.023_bib0085","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4049\/jimmunol.1401686","article-title":"Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo","volume":"194","author":"Das","year":"2015","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.lungcan.2020.05.023_bib0090","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.lungcan.2020.05.023_bib0095","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-12-4100","article-title":"Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors","volume":"73","author":"Duraiswamy","year":"2013","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.lungcan.2020.05.023_bib0100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/eji.201646583","article-title":"Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer","volume":"47","author":"van Hooren","year":"2017","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.lungcan.2020.05.023_bib0105","doi-asserted-by":"crossref","first-page":"8792","DOI":"10.1038\/ncomms9792","article-title":"Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab","volume":"4","author":"Mitsuhashi","year":"2015","journal-title":"Nat. Commun."},{"issue":"April (4)","key":"10.1016\/j.lungcan.2020.05.023_bib0110","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1165\/rcmb.2018-0098OC","article-title":"The tyrosine kinase inhibitor TAS-115 attenuates bleomycin-induced lung fibrosis in mice","volume":"60","author":"Koyama","year":"2019","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"10183","key":"10.1016\/j.lungcan.2020.05.023_bib0115","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated PD-L1-expressing, locally advanced or metastatic non-small-cell-lung cancer (KEYNOTE-042): a randomized, open-label, controlled, phase 3 trial","volume":"393","author":"Mok TSK","year":"2019","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.lungcan.2020.05.023_bib0120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3626","article-title":"The secret ally: immunostimulation by anticancer drugs","volume":"11","author":"Galluzzi","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.lungcan.2020.05.023_bib0125","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/2326-6066.CIR-16-0197","article-title":"Immunological mechanisms underneath the efficacy of cancer therapy","volume":"4","author":"Galluzzi","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.lungcan.2020.05.023_bib0130","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lungcan.2020.05.023_bib0135","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur. J. Immunol."},{"issue":"August (4)","key":"10.1016\/j.lungcan.2020.05.023_bib0140","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/ijc.25756","article-title":"Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells","volume":"129","author":"Rettig","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2020.05.023_bib0145","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2020.05.023_bib0150","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1158\/1078-0432.CCR-08-0037","article-title":"Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination","volume":"14","author":"Tseng","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.05.023_bib0155","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12026-015-8734-1","article-title":"Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model","volume":"64","author":"Huang","year":"2016","journal-title":"Immunol. Res."},{"issue":"18","key":"10.1016\/j.lungcan.2020.05.023_bib0160","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1158\/1078-0432.CCR-10-0733","article-title":"A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers","volume":"16","author":"Kodumudi","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.lungcan.2020.05.023_bib0165","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1158\/1535-7163.MCT-11-1014","article-title":"CTLA-4 blockade infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma","volume":"11","author":"Wu","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.lungcan.2020.05.023_bib0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061895","article-title":"Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity","volume":"8","author":"Lesterhuis","year":"2013","journal-title":"PLoS One"},{"issue":"24","key":"10.1016\/j.lungcan.2020.05.023_bib0175","doi-asserted-by":"crossref","first-page":"6345","DOI":"10.1158\/1078-0432.CCR-18-1231","article-title":"Gemcitabine synergizes with immune checkpoint inhibitors and overcome resistance in a preclinical model and mesothelioma patients","volume":"24","author":"Tall\u00f3n de Lara","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.05.023_bib0180","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie Anti-CTLA-4 and Anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell."},{"issue":"16","key":"10.1016\/j.lungcan.2020.05.023_bib0185","first-page":"4035","article-title":"Induction of systemic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12","volume":"59","author":"Nishioka","year":"1999","journal-title":"Cancer Res."},{"issue":"October (10)","key":"10.1016\/j.lungcan.2020.05.023_bib0190","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"issue":"4","key":"10.1016\/j.lungcan.2020.05.023_bib0195","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"6","key":"10.1016\/j.lungcan.2020.05.023_bib0200","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.lungcan.2020.05.023_bib0205","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1158\/1078-0432.CCR-16-0387","article-title":"Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells","volume":"23","author":"Horikawa","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.05.023_bib0210","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.lungcan.2020.05.023_bib0215","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10555-011-9281-4","article-title":"Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy","volume":"30","author":"Tartour","year":"2011","journal-title":"Cancer Metastasis Rev."},{"issue":"June (1)","key":"10.1016\/j.lungcan.2020.05.023_bib0220","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bbrc.2007.04.083","article-title":"Mechanism of vascular endothelial growth factor expression mediated by cisplatin in human ovarian cancer cells","volume":"358","author":"Zhong","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lungcan.2020.05.023_bib0225","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","article-title":"Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2020.05.023_bib0230","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1002\/ijc.32041","article-title":"Anti-PD-1\/PD-L1 therapy augments lenvatinib\u2019s efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer","volume":"144","author":"Gunda","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"20","key":"10.1016\/j.lungcan.2020.05.023_bib0235","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"9","key":"10.1016\/j.lungcan.2020.05.023_bib0240","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/JTO.0b013e3182208ee0","article-title":"Tunmor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model","volume":"6","author":"Wu","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.05.023_bib0245","doi-asserted-by":"crossref","first-page":"956","DOI":"10.4049\/jimmunol.0900437","article-title":"Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma","volume":"185","author":"Anraku","year":"2010","journal-title":"J. Immunol."},{"issue":"23","key":"10.1016\/j.lungcan.2020.05.023_bib0250","doi-asserted-by":"crossref","first-page":"7175","DOI":"10.1158\/1078-0432.CCR-19-0433","article-title":"The folate pathway inhibitor pemetrexed pleiotropically enhances effects of Cancer immunotherapy","volume":"25","author":"Schaer","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2020.05.023_bib0255","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3892\/ol.2015.3918","article-title":"Myeloid-derived suppressor cells enhance the expression of melanoma-associated antigen A4 in a Lewis lung cancer murine model","volume":"11","author":"Shi","year":"2016","journal-title":"Oncol. Lett."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220304463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220304463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:45:01Z","timestamp":1759236301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220304463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":51,"alternative-id":["S0169500220304463"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.05.023","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}